TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32867777

Group type: EXPERIMENTAL
Intervention: Drug abuse
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hookah
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Extramarital intercourse
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Gambling
Number of subjects: 2000
Study: 34913020

Group type: EXPERIMENTAL
Intervention: Ergocalciferol (50,000 IU per week for 2 months, then once every 2 weeks for 10 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35260317

Group type: EXPERIMENTAL
Intervention: Full ban on ENDS in Massachusetts
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Banning non-tobacco flavored ENDS
Number of subjects: 3

Group type: COMPARATOR
Intervention: Halted states (revoked ENDS bans)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control states (placebo tests)
Number of subjects: 3
Study: 34228505

Group type: EXPERIMENTAL
Intervention: Calaspargase (2,500 IU/m2/dose, every 3 weeks for 10 doses)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Pegaspargase (2,500 IU/m2/dose, every 2 weeks for 15 doses)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 239
Study: 33087221

Group type: EXPERIMENTAL
Intervention: Composite strip crowns (CSCs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: NuSmile preveneered stainless steel crowns (PVSSCs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: NuSmile zirconia crowns (ZCs)
Number of subjects: 49
Study: 35841057

Group type: EXPERIMENTAL
Intervention: Combination of nanofat subcutaneously and SVF intradermally
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nanofat subcutaneously (control group)
Number of subjects: 7
Study: 32302702

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Carboplatin + Nab-Paclitaxel (A+CnP)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Carboplatin + Nab-Paclitaxel (CnP)
Number of subjects: 1021
Study: 36104781

Group type: EXPERIMENTAL
Intervention: Structured physiotherapy with workplace dialogue
Number of subjects: 352

Group type: COMPARATOR
Intervention: Structured physiotherapy alone
Number of subjects: 352
Study: 34112627

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation (MOP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no MOP)
Number of subjects: 33
Study: 32362231

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9327

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 9327

Group type: EXPERIMENTAL
Intervention: Preexisting AF
Number of subjects: 9327

Group type: EXPERIMENTAL
Intervention: New-onset AF
Number of subjects: 9327

Group type: EXPERIMENTAL
Intervention: Preexisting AF with BP <120/80 mm Hg at 3 months
Number of subjects: 9327
Study: 32779544

Group type: EXPERIMENTAL
Intervention: MIP60 (60% maximal inspiratory pressure, 3×10 repetitions)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MIP30 (30% maximal inspiratory pressure, 3×20 repetitions)
Number of subjects: 21
Study: 32401418

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 32703623

Group type: EXPERIMENTAL
Intervention: ReDS-guided therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 108
Study: 33175970

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 36262374

Group type: EXPERIMENTAL
Intervention: PEMF therapy (1 mT for 10 min weekly for 16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 20
Study: 34878212

Group type: EXPERIMENTAL
Intervention: Individual results from the study
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Summary of overall trial results
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: A thank you for your contribution to the study
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Delivery by post
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hard copy of results
Number of subjects: 16
Study: 32866761

Group type: COMPARATOR
Intervention: Brivaracetam
Number of subjects: 12739

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 12739

Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 12739

Group type: COMPARATOR
Intervention: Carisbamate
Number of subjects: 12739

Group type: COMPARATOR
Intervention: 9 AEDs
Number of subjects: 12739
Study: 34488858

Group type: EXPERIMENTAL
Intervention: Subcutaneous IVM at 200 ?g/kg/48 h (Arm A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Subcutaneous IVM at 200 ?g/kg/48 h and oral Zn 20mg/8 h (Arm B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral IVM at 0.2 mg/kg/day (Arm C)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral IVM at 0.2 mg/kg/day and oral Zn 20mg/8 h (Arm D)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral Zn 20mg/8 h (Arm E)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo alone (Arm X)
Number of subjects: 180
Study: 33538345

Group type: EXPERIMENTAL
Intervention: Alternating blue (470 nm) and red (640 nm) light in two visits per week for 4 consecutive weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blue and red light treatments consecutively on the same visit for 4 consecutive weeks
Number of subjects: 30
Study: 33232629

Group type: EXPERIMENTAL
Intervention: PBMT 135 J
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PBMT 270 J
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PBMT 540 J
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no PBMT)
Number of subjects: 18
Study: 35639865

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 269

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 269

Group type: COMPARATOR
Intervention: Exercise plus diet
Number of subjects: 269
Study: 33662124

Group type: EXPERIMENTAL
Intervention: Oral prednisone (12-day postoperative taper)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Matched placebo tablets
Number of subjects: 72
Study: 32879954

Group type: EXPERIMENTAL
Intervention: Fluid Restriction (FR) 1 liter/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (NoTx)
Number of subjects: 46
Study: 35788727

Group type: EXPERIMENTAL
Intervention: Mindfulness yoga + conventional care
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 136
Study: 34494889

Group type: EXPERIMENTAL
Intervention: Immediate SSC (at birth)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Early SSC (at 60 minutes of life)
Number of subjects: 297
Study: 34987795

Group type: EXPERIMENTAL
Intervention: Nasal and oropharyngeal rinses with neutral electrolyzed water (SES), three times a day for 4 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no SES rinses)
Number of subjects: 170
Study: 35148396

Group type: EXPERIMENTAL
Intervention: Evening sleep schedule (15:00-23:00)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morning sleep schedule (09:00-17:00)
Number of subjects: 60
Study: 33705727

Group type: EXPERIMENTAL
Intervention: 3 µg with Algel-IMDG
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: 6 µg with Algel-IMDG
Number of subjects: 380

Group type: COMPARATOR
Intervention: 6 µg with Algel
Number of subjects: 380

Group type: COMPARATOR
Intervention: Algel alone
Number of subjects: 380
Study: 32481440

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 35365197

Group type: EXPERIMENTAL
Intervention: Letrozole and FSH
Number of subjects: 900

Group type: COMPARATOR
Intervention: FSH alone
Number of subjects: 900
Study: 34404147

Group type: EXPERIMENTAL
Intervention: Virtual training group
Number of subjects: 30
Study: 36151554

Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) plus usual care
Number of subjects: 476

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 476
Study: 32840871

Group type: EXPERIMENTAL
Intervention: Theory-based intervention in physical education (PE) designed to train self-control
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 116
Study: 36349973

Group type: EXPERIMENTAL
Intervention: Supplementary food and anti-infective treatments
Number of subjects: 1421
Study: 34061145

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) within 10 days of the index stroke; n=242
Number of subjects: 496

Group type: COMPARATOR
Intervention: Usual care consisting of external cardiac monitoring; n=250
Number of subjects: 496
Study: 32843659

Group type: EXPERIMENTAL
Intervention: 5-hour training regime with haptic sound-localisation
Number of subjects: 32

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 32
Study: 35602030

Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD)
Number of subjects: 29
Study: 33870923

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard plasma
Number of subjects: 74
Study: 34881370

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV) administered at enrolment (day 0)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (LAIV administered at the end of active follow-up, day 21)
Number of subjects: 330
Study: 32886192

Group type: EXPERIMENTAL
Intervention: BetaMe/Melon digital health programme (12 months duration)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 429
Study: 36428011

Group type: EXPERIMENTAL
Intervention: MDMA‐assisted psychotherapy (MDMA‐AP)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control pharmacotherapy trial
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: MDMA‐AP
Number of subjects: 94
Study: 32370202

Group type: EXPERIMENTAL
Intervention: Supervised functional exercise and exercise counseling (1st phase) followed by home-based exercise on non-dialysis days (2nd phase) for 8 weeks each
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supervised functional exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baseline DB score
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low OEE and low DB scores
Number of subjects: 40
Study: 35876941

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 19

Group type: COMPARATOR
Intervention: 30 g glucose
Number of subjects: 19

Group type: COMPARATOR
Intervention: 300 ml water
Number of subjects: 19
Study: 33284114

Group type: EXPERIMENTAL
Intervention: Two doses of intradermal f-IPV (administered at 14 and 36 weeks)
Number of subjects: 773

Group type: COMPARATOR
Intervention: Two doses of intramuscular IPV (administered at 14 and 36 weeks)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Three doses of intradermal f-IPV (administered at 10, 14, and 36 weeks)
Number of subjects: 773

Group type: COMPARATOR
Intervention: Three doses of intramuscular IPV (administered at 10, 14, and 36 weeks)
Number of subjects: 773
Study: 33884980

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.2 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 100
Study: 33551199

Group type: EXPERIMENTAL
Intervention: Fitbit program with telephone communication every two weeks for two months, then once during months four and five.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fitbit program with electronic communication (email/text).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fitbit program (both interventions).
Number of subjects: 46
Study: 32022371

Group type: EXPERIMENTAL
Intervention: 20 mg oral temazepam
Number of subjects: 0
Study: 33202337

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 32588515

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg/day for 6 months plus celecoxib 200 mg/day for 3 months
Number of subjects: 310

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg/day for 6 months
Number of subjects: 310
Study: 34953184

Group type: EXPERIMENTAL
Intervention: 0.20% chlorhexidine with hyaluronic acid mouthwash
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine mouthwash
Number of subjects: 46

Group type: COMPARATOR
Intervention: Basic periodontal therapy only
Number of subjects: 46
Study: 33292916

Group type: EXPERIMENTAL
Intervention: Videoconference administration of neuropsychological measures
Number of subjects: 48

Group type: COMPARATOR
Intervention: In-person administration of neuropsychological measures
Number of subjects: 48
Study: 33023497

Group type: EXPERIMENTAL
Intervention: Interprofessional medication assessment
Number of subjects: 512

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 512
Study: 35351204

Group type: EXPERIMENTAL
Intervention: Nutrition education program promoting fruit and vegetable consumption
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 74
Study: 35247974

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis CURE21, 1010 colony forming units/day for six weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum 299 (Lp299), 1010 colony forming units/day for six weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study: 32998108

Group type: EXPERIMENTAL
Intervention: ImKR (velocity feedback immediately after each repetition)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HalfKR (velocity feedback after the first half of repetitions of each set)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AvgKR (feedback of the average velocity of each set)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 15
Study: 36471186

Group type: EXPERIMENTAL
Intervention: Concurrent exercise training (CT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 59
Study: 34391410

Group type: EXPERIMENTAL
Intervention: Airflow with calcium carbonate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Airflow with sodium bicarbonate
Number of subjects: 30

Group type: COMPARATOR
Intervention: FlexiDisc (conventional polishing)
Number of subjects: 30
Study: 32496902

Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate (IT MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal Triple Therapy (ITT)
Number of subjects: 0
Study: 36457362

Group type: EXPERIMENTAL
Intervention: Group intervention (6-week intervention designed to improve psychosocial outcomes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual intervention (6-week intervention via video)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 33446472

Group type: EXPERIMENTAL
Intervention: Pingchan Granule (PCG)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 32413350

Group type: EXPERIMENTAL
Intervention: Structured reports
Number of subjects: 5155

Group type: COMPARATOR
Intervention: Freestyle reports
Number of subjects: 5155

Group type: EXPERIMENTAL
Intervention: Structured reports indicating 'no acute disease'
Number of subjects: 5155

Group type: EXPERIMENTAL
Intervention: 'No acute disease' impression
Number of subjects: 5155

Group type: EXPERIMENTAL
Intervention: 'Negative chest' impression
Number of subjects: 5155
Study: 35417778

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFA) supplementation for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 34159199

Group type: EXPERIMENTAL
Intervention: Resistance training exercise (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 60
Study: 35499363

Group type: EXPERIMENTAL
Intervention: Active hearing aids
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham hearing aids
Number of subjects: 37
Study: 34789000

Group type: EXPERIMENTAL
Intervention: Minimally invasive atraumatic restorative treatment and the Hall technique approaches (ART-HT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Delayed intervention group advised to seek dental care from their usual service provider
Number of subjects: 29
Study: 35583870

Group type: EXPERIMENTAL
Intervention: ROC
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: ROC+
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: BWL
Number of subjects: 271

Group type: COMPARATOR
Intervention: AC
Number of subjects: 271
Study: 33074950

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Carbon Dioxide (CO2)
Number of subjects: 262
Study: 32537740

Group type: EXPERIMENTAL
Intervention: Utilization of the ECG Belt to guide implant as well as postimplant programming
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Utilizing the ECG Belt to guide postimplant programming alone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-Belt control arm
Number of subjects: 400
Study: 36226977

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 32684099

Group type: EXPERIMENTAL
Intervention: Sesame Oil (SO)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Canola Oil (CO)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sesame-Canola Oil (SCO)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 77
Study: 33112254

Group type: EXPERIMENTAL
Intervention: Competent Adulthood Transition with Cognitive Behavioral Humanistic and Interpersonal Training
Number of subjects: 369

Group type: COMPARATOR
Intervention: Health education (active control)
Number of subjects: 369
Study: 33812736

Group type: EXPERIMENTAL
Intervention: High Mediterranean Diet Scores (MDS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low Mediterranean Diet Scores (MDS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stage 1-2 CKD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperkalemia
Number of subjects: 50
Study: 32134931

Group type: EXPERIMENTAL
Intervention: DMPA-IM
Number of subjects: 54

Group type: COMPARATOR
Intervention: non-HC
Number of subjects: 54
Study: 35967517

Group type: EXPERIMENTAL
Intervention: Naldemedine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32017867

Group type: EXPERIMENTAL
Intervention: Raise Your Resilience group intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 89
Study: 33809796

Group type: EXPERIMENTAL
Intervention: Low sodium meal plan (<0.95 mg/kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Typical sodium meal plan (>2 mg/kcal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low sodium meal plan
Number of subjects: 20
Study: 32406601

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 200
Study: 35012771

Group type: EXPERIMENTAL
Intervention: tEPA
Number of subjects: 151

Group type: COMPARATOR
Intervention: BMG
Number of subjects: 151
Study: 34468979

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0
Study: 32427555

Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic supra- and subgingival debridement + Er,Cr:YSGG laser application
Number of subjects: 59

Group type: COMPARATOR
Intervention: Full-mouth ultrasonic supra- and subgingival debridement + root planing with Gracey curettes
Number of subjects: 59
Study: 37027137

Group type: EXPERIMENTAL
Intervention: Habitual sleep efficiency of 75% to 84%
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Taking sleep medications once or twice a week
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Frequency of daytime dysfunction less than once a week
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Taking sleep medications less than once a week
Number of subjects: 498
Study: 32845061

Group type: EXPERIMENTAL
Intervention: Machine learning XGBoost model
Number of subjects: 19331

Group type: COMPARATOR
Intervention: Traditional logistic model
Number of subjects: 19331
Study: 32460882

Group type: EXPERIMENTAL
Intervention: Distribution-based methods
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: 0.2 SD and 1/3 SD distribution methods
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Simple imputation by mean score
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Multiple imputations techniques
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Using 3 measurement occasions
Number of subjects: 393
Study: 36229579

Group type: EXPERIMENTAL
Intervention: Repeat sequential two FLOX cycles and two immune checkpoint blockade (ICB) cycles
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control arm (oxaliplatin‐based Nordic FLOX regimen)
Number of subjects: 66
Study: 33200649

Group type: EXPERIMENTAL
Intervention: Continuous inner forearm cooling (COOL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No cooling (CONTROL)
Number of subjects: 11
Study: 32365607

Group type: EXPERIMENTAL
Intervention: Immediate Treatment (IT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 30
Study: 35841234

Group type: EXPERIMENTAL
Intervention: Soticlestat (≤300 mg twice daily, weight-adjusted)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 34090216

Group type: EXPERIMENTAL
Intervention: Olive oil-based intravenous lipid emulsion (OO-based IVLE)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Soybean oil-based intravenous lipid emulsion (SO-based IVLE)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups (OO and SO-based IVLE)
Number of subjects: 210
Study: 33988337

Group type: EXPERIMENTAL
Intervention: Standard-dose trivalent inactivated influenza vaccination (SDTIIV)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Double-dose trivalent inactivated influenza vaccination (DDTIIV)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Booster-dose trivalent inactivated influenza vaccination (BDTIIV)
Number of subjects: 176